SIFROL pramipexole dihydrochloride monohydrate 1.0 mg tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sifrol pramipexole dihydrochloride monohydrate 1.0 mg tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; povidone; maize starch; mannitol - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.

SIFROL pramipexole dihydrochloride monohydrate 250 microgram tablet blister pack Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sifrol pramipexole dihydrochloride monohydrate 250 microgram tablet blister pack

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; maize starch; povidone; colloidal anhydrous silica - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.

ATROVENT ADULT UNIT DOSE VIALS ipratropium bromide 500 micrograms/1 mL (as monohydrate) conventional inhalation ampoule Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

atrovent adult unit dose vials ipratropium bromide 500 micrograms/1 ml (as monohydrate) conventional inhalation ampoule

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 522 microgram/ml (equivalent: ipratropium bromide, qty 500 microgram/ml) - inhalation, conventional - excipient ingredients: sodium chloride; hydrochloric acid; purified water - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

ATROVENT ipratropium bromide 250 micrograms/mL (as monohydrate) conventional inhalation bottle Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

atrovent ipratropium bromide 250 micrograms/ml (as monohydrate) conventional inhalation bottle

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 0.261 mg/ml (equivalent: ipratropium bromide, qty 0.25 mg/ml) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; sodium chloride; hydrochloric acid; disodium edetate - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

ATROVENT UNIT DOSE VIALS ipratropium bromide 250 micrograms/1 mL (as monohydrate) conventional inhalation ampoule Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

atrovent unit dose vials ipratropium bromide 250 micrograms/1 ml (as monohydrate) conventional inhalation ampoule

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 261 microgram/ml (equivalent: ipratropium bromide, qty 250 microgram/ml) - inhalation, conventional - excipient ingredients: purified water; sodium chloride; hydrochloric acid - moderate asthmatic attacks; chronic forms of asthma; asthma in patients with diminished cardiac reserve; chronic obstructive bronchitis with bronchospasm; bronchospasm during or after surgery, use during assisted ventilation with a respirator. administration of atrovent via a nebuliser is intended for those patients who cannot use a metered dose aerosol.

Actilyse New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

actilyse

boehringer ingelheim (nz) limited - alteplase 10mg - injection with diluent - 10 mg - active: alteplase 10mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Actilyse New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

actilyse

boehringer ingelheim (nz) limited - alteplase 20mg - injection with diluent - 20 mg - active: alteplase 20mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Actilyse New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

actilyse

boehringer ingelheim (nz) limited - alteplase 50mg - injection with diluent - 50 mg - active: alteplase 50mg excipient: arginine nitrogen phosphoric acid polysorbate 80 water for injection - actilyse is indicated for fibrinolytic therapy in acute thrombotic artery occlusion to restore coronary artery patency, reduce infarct size, preserve ventricular function, prevent cardiac insufficiency and reduce mortality · 90 minutes (accelerated) dose regimen: for patients in whom treatment can be started within 6 h of symptom onset; · 3 hour dose regimen: for patients in whom treatment can be started between 6 - 12 hrs after symptom onset.

Atrovent New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

atrovent

boehringer ingelheim (nz) limited - ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous - aerosol inhaler, metered dose - 20 mcg/dose - active: ipratropium bromide monohydrate 0.021mg equivalent to 0.020 mg/dose ipratropium bromide anhydrous excipient: citric acid ethanol nitrogen norflurane purified water - atrovent is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis, emphysema and asthma.

Dixarit New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

dixarit

boehringer ingelheim (nz) limited - clonidine hydrochloride 25ug - tablet - 25 mcg - active: clonidine hydrochloride 25ug excipient: acacia amylodextrin calcium hydrogen phosphate dihydrate carnauba wax colloidal silicon dioxide indigo carmine   lactose monohydrate macrogol 6000 magnesium stearate maize starch methyl hydroxybenzoate povidone   propyl hydroxybenzoate purified talc sucrose titanium dioxide white beeswax